Sector News

Clariant welcomes Britta Fuenfstueck to executive committee

January 28, 2016
Chemical Value Chain

Clariant, a world leader in specialty chemicals, announced today the appointment of Britta Fuenfstueck as a new member of its Executive Committee. Britta Fuenfstueck, former CEO of the Clinical Products Division at Siemens Healthcare, will join Clariant on April 1, 2016.

“We are very pleased that Britta Fuenfstueck will join Clariant. With her extensive international experience as a senior executive in the technology industry, she will be a strong addition to our management team and will bring valuable insights and perspectives,” said Hariolf Kottmann, CEO. “I look forward to Britta Fuenfstueck’s contributions toward the long-term development of Clariant and her support for our top priority: to generate value for our customers, our employees, our company, and our shareholders.”

Britta Fuenfstueck (43) has been CEO of the Clinical Products Division at Siemens Healthcare since 2013. During her career with Siemens, she held various leadership positions, including CEO of the Molecular Imaging Business Unit, Vice President, Strategy and M&A for the Healthcare Sector, as well as Director, Product Portfolio and Planning, Marketing and Sales, for Siemens’ Magnetic Resonance Business Unit. Britta Fuenfstueck studied engineering physics at the Johannes Kepler University in Linz, Austria. She began her career with the Boston Consulting Group in 1998.

As of April 1, 2016, the Executive Committee of Clariant will consist of CEO Hariolf Kottmann, CFO Patrick Jany, Britta Fuenfstueck, and Christian Kohlpaintner.

Source: Clariant

Related News

February 28, 2021

Borealis to invest in new RTO to reduce CO2 emissions at Porvoo polyolefins plant

Chemical Value Chain

This equipment will significantly lower the site’s CO2 emissions, reduce flaring and save around 60 gigawatt hours (GWh) energy each year. Project kick-off is in February 2021, with completion planned for 2023.

February 28, 2021

Grace to acquire Albemarle’s fine chemistry business for $570 million

Chemical Value Chain

The acquisition significantly strengthens and expands Grace’s existing pharma portfolio. Pharma & Consumer is the largest, fastest growing and most profitable subsegment within Grace’s Materials Technologies business.

February 28, 2021

Solvay to carve out soda ash business

Chemical Value Chain

Solvay says it has decided to organize its soda ash and derivatives business into a separate and fully controlled legal structure.

Send this to a friend